Two-Year Efficacy and Safety Update from JAVELIN Merkel 200 Part A: A Registrational Study of Avelumab in Metastatic Merkel Cell Carcinoma Progressed on Chemotherapy

被引：0
|
作者：
Sandhu, S. [1 ]
Nghiem, P. [2 ]
Bhatia, S. [3 ]
Brohl, A. S. [4 ]
Hamid, O. [5 ]
Mehnert, J. M. [6 ]
Terheyden, P. [7 ]
Shih, K. C. [8 ]
Brownell, I. [9 ]
Lebbe, C. [10 ,11 ]
Lewis, K. D. [12 ]
Linette, G. P. [13 ]
Milella, M. [14 ]
Hennessy, M. [15 ]
Bajars, M. [15 ]
Hicking, C. [16 ]
D'Angelo, S. P. [17 ,18 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Washington, Med Ctr South Lake Union, Seattle, WA 98195 USA
[3] Univ Washington, Med Ctr, Seattle, WA 98195 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Angeles Clin & Res Inst, Los Angeles, CA USA
[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[7] Univ Lubeck, Lubeck, Germany
[8] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[9] NCI, Bethesda, MD 20892 USA
[10] St Louis Hosp, CIC, Paris, France
[11] St Louis Hosp, Dermatol, Paris, France
[12] Univ Colorado Denver, Sch Med, Aurora, CO USA
[13] Univ Penn, Philadelphia, PA 19104 USA
[14] IRCCS Regina Elena Natl Canc Inst, Rome, Italy
[15] EMD Serono Inc, Billerica, MA USA
[16] Merck KGaA, Darmstadt, Germany
[17] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[18] Weill Cornell Med Coll, New York, NY USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 53
页数：2
相关论文
共 42 条
  • [21] Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
    Nghiem, Paul
    Kaufman, Howard L.
    Bharmal, Murtuza
    Mahnke, Lisa
    Phatak, Hemant
    Becker, Juergen C.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1263 - 1279
  • [22] Patient (pt) experiences with avelumab in treatment-naive metastatic Merkel cell carcinoma (mMCC): Qualitative interview findings from a registrational clinical trial.
    Bharmal, Murtuza
    Lambert, Jeremy
    Russell, Jeffery Scott
    Lebbe, Celeste
    Chmielowski, Bartosz
    Hennessy, Meliessa
    Marrel, Alexia
    D'Angelo, Sandra P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [23] Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program (vol 8, e000313, 2020)
    Walker, J. W.
    Lebbe, C.
    Grignani, G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [24] Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
    D'Angelo, Sandra P.
    Russell, Jeffery
    Lebbe, Celeste
    Chmielowski, Bartosz
    Gambichler, Thilo
    Grob, Jean-Jacques
    Kiecker, Felix
    Rabinowits, Guilherme
    Terheyden, Patrick
    Zwiener, Isabella
    Bajars, Marcis
    Hennessy, Meliessa
    Kaufman, Howard L.
    JAMA ONCOLOGY, 2018, 4 (09)
  • [25] A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naive metastatic Merkel cell carcinoma: The MERKLIN 1 study
    Ascierto, P. A.
    van Akkooi, A. C. J.
    Nghiem, P.
    Hermann, F.
    Henneberg, J-P.
    Becker, J. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S901 - S902
  • [26] Open-label, multicenter Phase II Study to Investigate the Efficacy and Safety of Domatinostat in Combination with Avelumab in Patients with treatment-naive, metastatic Merkel Cell Carcinoma - the MERKLIN 1 Study
    Terheyden, P.
    van Akkooi, A.
    Ascierto, P. A.
    Nghiem, P.
    Henneberg, J.
    Hermann, F.
    Becker, J. C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 45 - 46
  • [27] Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.
    Apolo, Andrea B.
    Ellerton, John Allan
    Infante, Jeffrey R.
    Agrawal, Manish
    Gordon, Michael S.
    Aljumaily, Raid
    Britten, Carolyn D.
    Dirix, Luc
    Lee, Keun-Wook
    Taylor, Matthew H.
    Schoffski, Patrick
    Wang, Ding
    Ravaud, Alain
    Xiong, Junyuan
    Rosen, Galit
    Gulley, James L.
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Two-year efficacy and safety update from the phase III CheckMate 025 study of nivolumab versus everolimus in patients with advanced renal cell carcinoma (aRCC)
    Plimack, Elizabeth R.
    Motzer, Robert J.
    Escudier, Bernard
    Sharma, Padmanee
    Mcdermott, David F.
    George, Saby
    Hammers, Hans J.
    Carducci, Michael
    Tykodi, Scott S.
    Sosman, Jeffrey A.
    Choueiri, Toni K.
    Donskov, Frede
    Gurney, Howard
    Gauler, Thomas C.
    Ueda, Takeshi
    Zhao, Huanyu
    Berghorn, Elmer
    Wagstaff, John
    BJU INTERNATIONAL, 2016, 118 : 11 - 12
  • [29] First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.
    D'Angelo, Sandra P.
    Russell, Jeffrey
    Hassel, Jessica Cecile
    Lebbe, Celeste
    Chmielowski, Bartosz
    Rabinowits, Guilherme
    Terheyden, Patrick
    Brownell, Isaac
    Zwiener, Isabella
    Bajars, Marcis
    Hennessy, Meliessa
    Kaufman, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study
    van Akkooi, A. C. J.
    Ascierto, P. A.
    Becker, J. C.
    Nathan, P.
    Nghiem, P.
    Ostermeier, U.
    Reimann, P. G.
    Hermann, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S767 - S768
12345